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he ﬁbronectin (FN)-binding integrins 
 
 
 
4
 
 
 
1 and 
 
 
 
5
 
 
 
1
confer different cell adhesive properties, particularly
with respect to focal adhesion formation and migration.
After analyses of 
 
 
 
4
 
 
 
/
 
 
 
5
 
 
 
 A375-SM melanoma cell adhesion
to fragments of FN that interact selectively with 
 
 
 
4
 
 
 
1 and
 
 
 
5
 
 
 
1, we now report two differences in the signals trans-
duced by each receptor that underpin their speciﬁc adhesive
properties. First, 
 
 
 
5
 
 
 
1 and 
 
 
 
4
 
 
 
1 have a differential require-
ment for cell surface proteoglycan engagement for focal
adhesion formation and migration; 
 
 
 
5
 
 
 
1 requires a pro-
teoglycan coreceptor (syndecan-4), and 
 
 
 
4
 
 
 
1 does not.
T
 
Second, adhesion via 
 
 
 
5
 
 
 
1 caused an eightfold increase in
protein kinase C
 
  
 
(PKC
 
 
 
) activation, but only basal PKC
 
 
 
activity was observed after adhesion via 
 
 
 
4
 
 
 
1. Pharmaco-
logical inhibition of PKC
 
 
 
 and transient expression of
dominant-negative PKC
 
 
 
, but not dominant-negative PKC
 
 
 
or PKC
 
 
 
 constructs, suppressed focal adhesion formation
and cell migration mediated by 
 
 
 
5
 
 
 
1, but had no effect on
 
 
 
4
 
 
 
1. These ﬁndings demonstrate that different integrins
can signal to induce focal adhesion formation and migration
by different mechanisms, and they identify PKC
 
 
 
 signaling as
central to the functional differences between 
 
 
 
4
 
 
 
1 and 
 
 
 
5
 
 
 
1.
 
Introduction
 
The adhesive interactions of cells with ECM molecules have
wide-ranging effects on cellular differentiation and tissue
structure in vivo (Bouvard et al., 2001; Hynes, 2002). At the
molecular level, these adhesion-dependent signals are mediated
by clustering of integrin adhesion receptors, organization of
the actin cytoskeleton, and congregation of signaling adaptors
and enzymes into specialized morphological structures, includ-
ing focal adhesions, focal complexes, and fibrillar adhesions
(Schoenwaelder and Burridge, 1999; Yamada and Geiger,
1997). The composition of different adhesive contacts is
diverse, and therefore suggestive of a varied contribution of
these receptors to ECM sensing, intracellular signaling, and
cytoskeletal organization, but the key molecular events deter-
mining this diversity are unknown. In cultured cells, integrins
differentially regulate morphology and cytoarchitecture, fluxes
through signaling pathways, and the expression of specific
genes (Huhtala et al., 1995; Burridge and Chrzanowska-
Wodnicka, 1996; Choquet et al., 1997), but the mechanisti-
cally important variations in the signals transduced by different
receptors are poorly defined.
Particularly distinctive cellular responses have been observed
on substrates recognized by the fibronectin (FN)*-binding
integrin 
 
 
 
4
 
 
 
1. For example, 
 
 
 
4
 
 
 
1 engagement promotes
enhanced cell migratory activity while reducing spreading
and focal adhesion formation. Elegant studies using integrin
chimeras demonstrated that these functional properties were
conferred by the 
 
 
 
4 cytoplasmic domain (Chan et al., 1992;
Kassner et al., 1995), which in turn suggested that this domain
either modulates association of cytoskeletal and signaling
molecules with its partner 
 
 
 
1 subunit differently to other
 
 
 
1-associated 
 
 
 
 subunits, or that it interacts directly with
cytoskeletal and signaling molecules. The latter hypothesis is
supported by the fact that 
 
 
 
4 can bind directly to paxillin,
and that this association contributes to the reduction of
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spreading and promotion of migration (Liu et al., 1999, Liu
and Ginsberg, 2000).
The signaling mechanisms that determine the specific
functional properties of other integrins are largely unknown,
although work from a number of laboratories has demon-
strated that 
 
 
 
5
 
 
 
1-dependent focal adhesion formation re-
quires engagement of (and signaling via) a syndecan core-
ceptor (Woods and Couchman, 2001; Bass and Humphries,
2002). Initially, plating of cells onto the isolated central
cell–binding domain (CCBD) and heparin-binding domain
(HBD) of FN was shown to promote attachment, but to be
insufficient for focal adhesion formation (Izzard et al., 1986;
Woods et al., 1986); however, addition of soluble HBD to
cells pre-spread on a CCBD fragment triggered vinculin re-
cruitment and actin stress fiber formation (Woods et al.,
1986). The site responsible for this activity was narrowed
down to a 29-amino acid sequence within the type III repeat
13 of FN (Bloom et al., 1999). Of the four known members
of the syndecan family of proteoglycans, only syndecan-4
has been found in focal adhesions (Woods and Couchman,
1994; Baciu and Goetinck, 1995). Treatment of cells with
anti-syndecan-4 antibody was also found to trigger focal ad-
hesion formation in cells adherent to the CCBD of FN (Sa-
oncella et al., 1999), and fibroblasts from syndecan-4 knock-
out mice were unable to respond to the HBD of FN
(Ishiguro et al., 2000), implicating syndecan-4 as a key re-
ceptor for focal adhesion formation on FN. In serum-starved
cells, syndecan-4 was absent from focal adhesions, but was
recruited by activation of PKC (Woods and Couchman,
1992; Baciu and Goetinck, 1995). Overexpression of synde-
can-4 increased focal adhesions (Echtermeyer et al., 1999),
whereas a COOH-terminal truncation mutant acted as a
dominant-negative inhibitor of focal adhesion formation
(Longley et al., 1999).
Although the role of syndecans in 
 
 
 
4
 
 
 
1-mediated adhe-
sion is unknown, it is intriguing that the binding sites for
both molecules overlap within FN. The 
 
 
 
4
 
 
 
1-binding do-
main of FN is primarily located in the type III connecting
segment (IIICS; Wayner et al., 1989), which is adjacent to
the major HBD, the COOH-terminal heparin binding do-
main of fibronectin (HepII). Three sites each for integrin
and heparin binding have been pinpointed within the
HepII/IIICS region (Humphries et al., 1986, 1987; Mc-
Carthy et al., 1988, 1990; Wayner et al., 1989; Barkalow
Figure 1. Schematic diagram of FN and recombinant 
fragments used in these studies. FN comprises three types 
of polypeptide module termed types I, II, and III. The 
CCBD, which binds  5 1, comprises an RGD tripeptide 
site in III-10 and a synergy site in III-9. The alternatively 
spliced IIICS, which binds  4 1, contains the peptide 
sequences LDV (in the NH2-terminal splice segment, IIICS-A) 
and REDV (in IIICS-C). The main heparin-binding site 
fragment of FN (HepII) comprises III12–14. The main 
heparin-binding site in FN (GAG-A) is located in III-13, 
and additional heparin-binding sites are found in IIICS-B 
(GAG-B) and III-14 (GAG-C). The three FN fragments used 
in these studies are 50K (III6–10), H/120 (III12–15, including 
a full-length 120-amino acid IIICS region), and H/0 (III12–15, 
without the IIICS).
 
Table I. 
 
Focal adhesion formation on FN fragments
 
a
 
Substrate % Spreading without H/0 % Spreading with H/0 % Cells with focal adhesions 
(without H/0)
% Cells with focal adhesions 
(with H/0)
 
H/120 47 
 
 
 
 5 45 
 
 
 
 5 46 
 
 
 
 3 47 
 
 
 
 5
H/120-GAG-ABC 48 
 
 
 
 3 50 
 
 
 
 5 52 
 
 
 
 6 56 
 
 
 
 3
50K 52 
 
 
 
 2 75 
 
 
 
 3 14 
 
 
 
 1 86 
 
 
 
 1
 
b
 
Substrate % Spreading with H/0 % Spreading with H/0 
and heparin
% Cells with focal adhesions 
(with H/0)
% Cells with focal adhesions 
(with H/0 and heparin)
 
H/120 42 
 
 
 
 3 44 
 
 
 
 5 43 
 
 
 
 2 42 
 
 
 
 3
H/120-GAG-ABC 46 
 
 
 
 4 48 
 
 
 
 3 51 
 
 
 
 4 50 
 
 
 
 2
50K 74 
 
 
 
 2 51 
 
 
 
 4 89 
 
 
 
 1 13 
 
 
 
 2
 
a
 
A375-SM cells were seeded onto coverslips coated with 10 
 
 
 
g/ml H/120, H/120-GAG-ABC, or 50K, and the percentage of cells spreading and forming fo-
cal adhesions in the presence or absence of 5 
 
 
 
g/ml soluble H/0 was estimated by phase-contrast microscopy and immunocytochemistry, respectively.
 
b
 
The effects of co-incubation of 100 
 
 
 
g/ml heparin and 5 
 
 
 
g/ml soluble H/0 were estimated.T
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and Schwarzbauer, 1991; Mould and Humphries, 1991;
Mould et al., 1991; Mostafavi-Pour et al., 2001). The over-
lapping locations of these sites, in part revealed by x-ray
crystallography (Sharma et al., 1999), suggest a close coor-
dination between integrin and proteoglycan binding. Here,
using melanoma cells that express both 
 
 
 
4
 
 
 
1 and 
 
 
 
5
 
 
 
1,
we have investigated the mechanisms underlying focal ad-
hesion formation and cell migration mediated by engage-
ment of the HepII/IIICS region of FN, and compared this
to the CCBD.
Figure 2. Double immunofluorescence 
staining for vinculin and integrin  1 
in A375-SM cells spread on different 
adhesive substrates. Cells were incubated 
for 2 h on 10  g/ml of each substrate, with 
or without a further 30 min incubation 
with 5  g/ml H/0 or 1:50 anti-syndecan-4. 
Heparin was added at 100  g/ml 
simultaneously with H/0. Cells were fixed, 
permeabilized, and stained for vinculin 
(green) and integrin  1 (red). (A–C) Cells 
spread on 50K alone. The arrowhead in 
the merged image (C) indicates integrin
 /
vinculin
  clusters. (D–F) Cells prespread 
on 50K for 2 h followed by addition 
of H/0. The arrowhead in F indicates 
colocalization of vinculin and integrin 
 1. (G–I) Cells prespread on 50K followed 
by treatment with H/0 in the presence 
of heparin. The arrowhead in I again 
indicates integrin
 /vinculin
  clusters. 
(J–L) Cells prespread on 50K followed by 
addition of anti-syndecan-4 antibody. The 
arrowhead in L indicates colocalization 
of vinculin and integrin  1. Cells spread 
on either H/120 (M–O) or H/120 treated 
with H/0 (P–R) exhibit colocalization of 
vinculin and integrin  1 (arrowheads in 
O and R). Addition of heparin and H/0 
to cells prespread on H/120 (S–U) had 
no discernible effect. Bar, 20  m.T
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Results
Focal adhesion formation mediated by immobilized 
cell-binding domains of FN
To compare the role of syndecans in focal adhesion formation
mediated by the integrins  4 1 and  5 1, A375-SM mela-
noma cells were plated on defined fragments of FN that inter-
act specifically with each receptor (Fig. 1). A375-SM cells
have previously been shown to express  4 1 and  5 1
(Mould et al., 1990), and we have found by FACS analysis
that they also express syndecan-4 (unpublished data). When
cells were plated onto a recombinant 50K fragment spanning
the CCBD of FN (recognized by  5 1), less than 15% of
spread cells formed vinculin-containing focal adhesions (Ta-
ble I a; Fig. 2 A). Although vinculin was rarely concentrated at
sites of attachment, it was notable that these sites did contain
 5 (unpublished data) and  1 integrins (Fig. 2 B), suggesting
that integrin engagement and clustering had been dissociated
from assembly of cytoskeletal structures. It is also notable that
talin,  -actinin, focal adhesion kinase, and paxillin were ab-
sent from adhesion contacts (unpublished data). When cells
were seeded on 50K and the medium was supplemented with
a low concentration of soluble heparin-binding fragment of
FN (5  g/ml H/0), there was a significant increase in the per-
centage of spread cells (from 40–50% to 70–80%), and al-
most 90% of the spread cells now formed vinculin- and inte-
grin-containing focal adhesions (Table I a; Fig. 2, D–F). The
stimulatory effect of H/0 was abolished by co-incubation with
heparin (Table I b; Fig. 2, G–I), and could be mimicked by
addition of soluble anti-syndecan-4 mAb 5G9 (Fig. 2, J–L).
These results confirm the synergistic link between integrin
 5 1 and syndecan-4 for focal adhesion formation.
When A375-SM cells were seeded onto the recombinant
H/120 fragment of FN, which includes both the heparin/
syndecan-binding sites and  4 1 integrin-binding sites in
the HepII and IIICS regions, respectively, almost 50% of
the spread cells formed focal adhesions (Table I a; Fig. 2,
M–O), and exogenous addition of soluble H/0 had no addi-
tional stimulatory effect (Table I a; Fig. 2, P–R). Although
this result was anticipated, as H/120 includes both integrin-
and syndecan-binding sites, it was surprising that addition
of 100  g/ml heparin did not affect focal adhesion forma-
tion on H/120 (Table I b; Fig. 2, S–U).
Glycosaminoglycan–binding sites within the HepII/IIICS 
region are not needed for focal adhesion formation
As one approach to determine whether integrin  4 1 re-
quired a syndecan coreceptor to trigger focal adhesion for-
mation, site-directed mutagenesis was performed on H/120
to remove all of its potential GAG-binding sites (found in
type III repeats 13 and 14, and the IIICS-B region; Fig.
1). All arginine and lysine residues in these regions were
mutated to serine, and the mutant protein (termed H/120-
GAG-ABC) was prepared as a GST fusion protein in bacte-
ria. After purification, the protein was analyzed by SDS-
PAGE under reducing conditions.
To assess folding of H/120-GAG-ABC, an ELISA assay was
performed in which the binding of a panel of HepII/IIICS
mAbs was determined. Some of these mAbs, including 9E9
and 16E6, do not Western blot, and therefore recognize con-
formational epitopes within FN. As shown in Fig. 3 A, all
mAbs recognized H/120-GAG-ABC to a similar extent to na-
tive H/120 with the exception of 9E9, where binding was re-
duced by 50%. It is possible that one or more arginine or
lysine residues contribute to the epitope for this mAb. The
binding of biotinylated heparin to the mutant protein was
Figure 3. Characterization of recombinant H/120-GAG-ABC. 
(A) ELISA assay showing the binding of HepII (9E9, 16E6, 36C9, 
39B6, 26G10, and 19B7), IIICS-B (18D8) and IIICS-C (10G6) mAbs 
to immobilized H/120 (solid bars) and its heparin-binding deficient 
mutant H/120-GAG-ABC (open bars), each coated at 10  g/ml. 
(B) Attachment of A375-SM melanoma cells to native H/120 (closed 
diamonds) and H/120-GAG-ABC (open circles). The level of 
nonspecific binding, determined from A375-SM melanoma cell 
attachment to wells coated with BSA alone, was subtracted. Values 
shown in both panels are mean   SD of triplicate wells.T
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then investigated. The level of binding to H/120-GAG-ABC
was reduced by  98% compared with that of native H/120,
and was not significantly different from the background, indi-
cating that all key heparin-binding sites had been removed
(unpublished data). Recombinant native and mutated pro-
teins were then tested for their ability to support A375-SM
melanoma cell adhesion. The proteins supported attachment
in a dose-dependent manner (Fig. 3 B). Attachment to native
H/120 variant was maximal at a level of 80%, and a coating
concentration of  0.7  g/ml was required for half-maximal
attachment. H/120-GAG-ABC showed only slightly lower
activity, with a maximal level of cell attachment of  65% and
a coating concentration of 1.6  g/ml being required for half-
maximal attachment. Finally, H/120-GAG-ABC was unable
to trigger vinculin recruitment to focal adhesions when A375-
SM cells were prespread on 50K (unpublished data).
The ability of H/120-GAG-ABC to support focal adhe-
sion formation and microfilament polymerization was then
assessed by double immunofluorescence microscopy using
anti-vinculin antibody and rhodamine-conjugated phalloi-
din. As shown in Fig. 4 and quantitated in Table I, cells
seeded on either H/120 or H/120-GAG-ABC were of a sim-
ilar shape, and both the number and location of focal adhe-
sions was indistinguishable. Identical results were obtained
when A375-SM cells were plated onto either CS1 peptide
(as an IgG conjugate) or recombinant VCAM-1-Fc (unpub-
lished data; CS1 is a synthetic peptide containing the major
 4 1 binding site within H/120, and VCAM-1 is an alter-
native   4 1 ligand; neither protein binds heparin). To-
gether, these results indicate that focal adhesion formation
mediated by  4 1 does not require simultaneous engage-
ment of a syndecan coreceptor.
Role of PKC  activation in focal adhesion formation 
via  4 1 or  5 1
To test the involvement of PKC  in focal adhesion forma-
tion, the activation of the enzyme was measured using West-
ern blotting. A375-SM cells adherent to either H/120, H/
120-GAG-ABC, 50K, or 50K   soluble H/0 were deter-
gent-extracted, and lysates were blotted with either a pan-
anti-PKC  antibody (MC5) or an antiserum that detects ac-
tivated PKC  (PPA182). Levels of PKC  were quantitated
by densitometry. The level of expression of PKC  was the
same for all adhesive substrata, but levels of phosphorylation
differed (Fig. 5). Thus, addition of H/0 to cells prespread on
50K potentiated the level of phosphorylation of PKC  eight-
fold. However, H/120 and H/120-GAG-ABC induced simi-
lar levels of PKC  phosphorylation that were indistinguish-
able from the basal level observed on 50K alone (Fig. 5).
Consistent with these results, pharmacological inhibition
of PKC  with bisindolylmaleimide (BIM) blocked vinculin
recruitment to focal adhesions induced by H/0 addition to
cells seeded on 50K (Fig. 6 A, panels A, D, and G). By con-
trast, little change was observed in integrin  1 distribution
(Fig. 6 A, panels B, E, and H). Vinculin and  1 integrin re-
cruitment induced by H/120 were not substantially affected
by BIM (Fig. 6 B; quantitated in Table II), although focal
adhesions were not as well organized.
Role of PKC signaling in A375-SM cell migration 
mediated by  4 1 and  5 1
To test whether the signaling differences underlying focal
adhesion formation mediated by  4 1 and  5 1 were also
observed for cell migration, A375-SM cells were plated on
recombinant FN fragments, left to form a confluent mono-
Figure 4. Focal adhesion and actin stress fiber formation in A375-SM melanoma cells seeded on H/120 or H/120-GAG-ABC. Cells were 
incubated for 2 h on H/120 (A–C) or H/120-GAG-ABC (D–F), fixed and dual-stained for vinculin (A and D) and actin (B and E). Arrows in the 
merged images (C and F) indicate localization of vinculin at the ends of actin bundles. Bar, 20  m.T
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layer overnight, and then scratch-wounded. Under the con-
ditions of this assay, there is a lag phase of  6 h during
which the cells recover and re-spread, followed by a progres-
sive closure of the wound over the next 24–30 h. Cells failed
to migrate when adherent to 50K alone, but treatment with
soluble H/0 at the time of wounding stimulated  5 1-
dependent migration. When cells were seeded on either H/120
or H/120-GAG-ABC, equivalent rates of  4 1-dependent
migration were observed (unpublished data). These findings
indicate that  5 1 requires syndecan engagement in order
to promote migration, but  4 1 does not.
To examine whether the differential dependence of  4 1
and   5 1 on PKC signaling was manifested during cell
movement as well as during focal adhesion formation, the
sensitivity of A375-SM cell migration to inhibitors of PKC
was tested in a wounding assay. For these studies, the early
phase of migration between 6 h and 12 h after wounding
was examined. Initially, the effects of the broad spectrum
PKC inhibitor, BIM, were tested. As shown in Fig. 7 (and
Videos 1–4, available at http://www.jcb.org/cgi/content/
full/jcb.200210176/DC1), addition of BIM 6 h after
wounding prevented wound closure on a 50K   H/0 sub-
strate, but had no discernible effect on H/120-mediated mi-
gration. A DMSO vehicle control showed no inhibition.
Thus, the substrate-specific inhibition of focal adhesion for-
mation by BIM was also seen for cell migration.
Although BIM exhibits good specificity for PKC, we also
attempted to perturb A375-SM migration using a domi-
nant-negative approach. Mutant forms of PKC isoforms,
tagged with GFP, were transfected into A375-SM tran-
siently, and then their ability to close wounds was exam-
ined. Initially, wild-type pEGFP-PKC  (WT) and the
double mutant pEGFP-PKC -A25E-K368M were tested.
A25E is a pseudosubstrate mutation that exposes the DAG/
TPA-binding site and catalytic site. K368M is a mutation in
the ATP-binding site that leaves the enzyme catalytically in-
active. Thus, pEGFP-PKC -A25E-K368M is inert, but
TPA-responsive. On a 50K substrate in the presence of solu-
ble H/0, transfection of pEGFP-PKC -WT, either with
(Fig. 8 A and Video 5) or without (unpublished data) TPA
treatment 6 h after wounding, had no discernible effect
on cell migration into the wound. When A375-SM cells
transfected with dominant-negative pEGFP-PKC -A25E-
K368M were examined in the absence of TPA, migration
again occurred normally (Fig. 8 B and Video 6). However,
addition of TPA to recruit pEGFP-PKC -A25E-K368M to
the plasma membrane led to an almost complete blockade
of cell movement (Fig. 8 C and Video 7). As shown most
clearly in the video, GFP-expressing cells remained virtually
motionless, exhibiting only occasional membrane ruffling
and protrusion. However, nontransfected cells that lacked
detectable GFP migrated past them and filled the wound.
As an additional control, cells were transfected with
pEGFP-PKC -T497A, a substrate-binding mutant that can
also act as a dominant-negative inhibitor. This mutant also
Figure 5. PKC  activation in cells adhering via  5 1 or  4 1. 
(A) Western blot analysis of total PKC  levels (top; detected with 
MC5 antibody) or activated PKC  (bottom; detected with PPA182 
antibody) in A375-SM cells seeded on 50K H/0 (lane 1), 50K (lane 
2), H/120 (lane 3), and H/120-GAG-ABC (lane 4). (B) Densitometric 
analysis of A. Results are the mean   SE of three separate experiments, 
of which A is representative.
Table II. Focal adhesion formation in the presence or absence of PKC  inhibitor
Substrate % Spreading control % Spreading (BIM) % Cells with focal adhesions 
(control)
% Cells with focal adhesions 
(BIM)
H/120 44   5 45   4 44   4 42   2
H/120-GAG-ABC 48   6 51   4 56   2 52   5
50K 54   3 51   3 15   3 12   2
50K   soluble H/0 76   4 52   6 89   5 24   3
A375-SM cells were seeded onto coverslips coated with 10 mg/ml native H/120, H/120-GAG-ABC, or 50K (with or without addition of 5 mg/ml soluble
H/0), and were co-incubated with 10 mg/ml bisindolylmaleimide (BIM) or DMSO as control. Cell spreading and focal adhesion formation were then
estimated by phase-contrast microscopy and immunocytochemistry, respectively.T
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prevented A375-SM cell migration on a 50K   H/0 sub-
strate (unpublished data). To probe the contribution of
PKC  to cell migration mediated by  4 1, pEGFP-PKC -
A25E-K368M–transfected cells were seeded on H/120 and
wounded. In contrast to the findings on 50K   H/0, domi-
nant-negative PKC  had no effect on wound closure (Fig. 8
D and Video 8), again suggesting that  4 1 does not de-
pend on this enzyme.
Because dominant-negative PKC  might also block the ac-
tivity of other PKC isoforms by competition for substrates,
Figure 6. Effects of PKC  inhibition on vinculin and integrin  1 distribution. (A) A375-SM cells were seeded onto 50K (A–C), 50K H/0 
(D–F), or 50K H/0 in the presence of 10  g/ml BIM (G–I), and dual-stained for vinculin (A,D, and G) and integrin  1 (B,E, and H). Untreated 
cells received DMSO as a control. (B) The same experiment was performed for cells seeded onto H/120 without (J–L) or with (M–O) BIM 
treatment. Bar, 20  m.T
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we performed control experiments with dominant-negative
mutants of PKC  and PKC . As shown in Fig. 9 (A and B)
and Videos 9 and 10, transfection with either dominant-neg-
ative pEGFP-PKC -K376M and pEGFP-PKC -K281M,
with or without TPA treatment, did not reduce A375-SM
migration on 50K   H/0. This suggests that the dominant-
negative effects of pEGFP-PKC -A25E-K368M are specific
to the   isoform. Interestingly, transfection of wild-type
pEGFP-PKC , and treatment with TPA, led to a suppres-
sion of migration (Fig. 9 C and Video 11). This result is con-
sistent with the previously reported syndecan-4–dependent
inhibitory effect of PKC  on PKC  (Murakami et al., 2002).
Together, these results demonstrate that migration mediated
by  4 1 and  5 1 exhibits the same differential dependency
on PKC  activity as focal adhesion formation.
Discussion
In this report, we have compared the mechanisms of focal ad-
hesion formation and cell migration used by A375-SM mela-
noma cells when adhering to FN via the integrins  4 1 and
 5 1. Melanoma cells were selected for these works because
they express both integrins, as well as heparan and chon-
droitin sulfate-containing proteoglycans (Iida et al., 1998).
Our major novel findings are as follows: (1)  5 1 and  4 1
have a differential requirement for cell surface proteoglycan
engagement for both focal adhesion formation and migra-
tion;  5 1 requires a proteoglycan coreceptor (syndecan-4),
and  4 1 does not; (2) focal adhesion formation and migra-
tion via the two integrins involve activation of different sig-
naling pathways;  5 1/syndecan-4 depends on the catalytic
activity of conventional PKC isotypes and signals specifically
to activate PKC , and  4 1 occupancy does not; and (3)
transfection of dominant-negative PKC isoforms identify
PKC  as the key signaling enzyme responsible for the differ-
ence in regulation of  4 1 and  5 1 function. Together,
these works demonstrate that the signals controlling integrin-
mediated focal adhesion formation and cell translocation are
not the same for each receptor, and they define PKC  activa-
tion as a key difference in the signaling pathways controlling
the function of  4 1 and  5 1.
Initially, we were able to confirm previous reports that
cells fail to form focal adhesions, or to migrate, on FN frag-
ments spanning the CCBD unless a heparin-binding frag-
ment is added in soluble form (Izzard et al., 1986; Woods et
al., 1986). Using Western blotting to detect activated PKC 
and pharmacological or dominant-negative inhibition, we
have also confirmed a requirement for PKC  for focal adhe-
sion formation via  5 1/syndecan-4. In contrast to these
findings,   4 1-binding ligands stimulated focal adhesion
formation without addition of a heparin-binding fragment,
and such supplementation did not augment focal adhesion
formation. Furthermore, PKC  was not activated, and nei-
ther soluble heparin, BIM, nor dominant-negative PKC 
blocked focal adhesion formation. These findings indicate
that engagement of syndecan-4 with the HBD of FN is not
needed for focal adhesion formation via  4 1, and either
that separate signaling mechanisms are used by the two inte-
grins to recruit cytoskeletal proteins to focal adhesions, or
 4 1 is able to bypass the requirement for syndecan-4–
Figure 7. Effects of PKC  inhibition on integrin-mediated migration. 
The migration of A375-SM cells into scratch wounds on either 
(A) a 50K substrate in the presence of soluble H/0 or (B) an H/120 
substrate was examined without treatment (left panels) or in the 
presence of 10  g/ml BIM (right panels). Still images were captured 
at the indicated times after wounding. The edges of the original 
wound are marked with dashed lines. Bars, 100  m.T
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mediated signaling. Given the currently indistinguishable gross
composition of  5 1- and  4 1-containing focal adhe-
sions, we favor the latter explanation, and we hypothesize
that some of the earliest events in integrin signaling differ
between  4 1 and  5 1.
It is now well-established that  4 1 has a number of un-
usual properties (Chan et al., 1992; Kassner et al., 1995),
and it is conceivable that the “gearing” of  4 1 to the cy-
toskeleton differs from other integrins. The recent finding
that the cytoplasmic domain of  4 interacts directly and
specifically with the signaling adaptor paxillin (Turner,
2000) may contribute to these different properties (Liu et
al., 1999, Liu and Ginsberg, 2000; Han et al., 2001). PIX
(Manser et al., 1998) is a nucleotide exchange factor for
both Cdc42 and Rac1, and its recruitment by paxillin
(through PKL) may potentially enhance membrane ruffling
and protrusion through these Rho family GTPases. On the
other hand, an integrin such as  5 1, which does not bind
paxillin but directly activates PKC , may stimulate Rho
GTPase activities, in a PKC-dependent manner. This hy-
pothesis is consistent with several lines of evidence that Rac1
may act downstream of PKC in the control of cell migra-
tion. In melanoma cells, for instance, TPA-induced lamelli-
podium formation is Rac1-dependent (Ballestrem et al.,
2000). By using dominant inhibitory constructs, the activity
states of several small GTPases, including Rac1, have been
shown to influence TPA-induced disassembly/reassembly of
actin stress fibers and focal adhesions in MDCK cells (Ima-
mura et al., 1998). Also, in NIH3T3 cells, growth factor-
induced Rac1 activation is sensitive to PKC inhibition, sug-
Figure 8. Effects of wild-type or dominant-negative PKC  overexpression on integrin-mediated migration. A375-SM cells were transiently 
transfected with various pEGFP-PKC  constructs and then tested for their ability to migrate into wounds on either a 50K substrate in the presence 
of soluble H/0 or an H/120 substrate. Still images were captured at the indicated times after wounding, and separate phase, EGFP, and merged 
images are shown (from left to right). (A) pEGFP-PKC -WT–transfected cells on 50K   H/0 in the presence of 5 ng/ml TPA; (B) pEGFP-PKC -
A25E-K368M–transfected cells on 50K   H/0 in the absence of TPA; (C) pEGFP-PKC -A25E-K368M–transfected cells on 50K   H/0 in the 
presence of 5 ng/ml TPA; (D) pEGFP-PKC -A25E-K368M–transfected cells on H/120 in the presence of 5 ng/ml TPA. Bars, 50  m.T
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gesting a hierarchical relationship between the two signaling
proteins (Buchanan et al., 2000).
In an attempt to identify the PKC isoform responsible for
 5 1-dependent migration, we used a dominant-negative
overexpression approach. Overexpression of dominant-nega-
tive pEGFP-PKC  (A25E-K368M double mutant) abro-
gated   5 1-dependent migration in a TPA-dependent
manner. Two additional dominant-negative constructs
were tested in the same assay, pEGFP-PKC -K376M
and pEGFP-PKC -K281M. As neither was able to perturb
 5 1-dependent migration, this provides a clear indication
that PKC  plays a specific role. Interestingly, overexpression
of wild-type PKC  did retard migration, a result that is con-
sistent with a recent paper reporting a syndecan-4–depen-
dent inhibitory effect of PKC  on PKC  (Murakami et al.,
2002). PKC  was shown to phosphorylate the cytoplasmic
domain of syndecan-4 and thereby prevent PKC  binding.
Therefore, it seems likely that the synergy between integrin
 5 1 and syndecan-4 for adhesion and migration relies on
the same regulatory pathway.
The downstream targets of PKC  phosphorylation during
 5 1-mediated adhesion and migration are not well de-
fined; however, PKC  has been shown to bind directly to
syndecan-4 in an interaction mediated by its catalytic do-
main (Oh et al., 1997a, b; Horowitz and Simons, 1998). In
addition, phosphatidylinositol-4,5-bisphosphate (PIP2) ap-
pears to make a key contribution to syndecan function
through its ability to bind to the variable region of the synde-
can-4 cytoplasmic domain (Oh et al., 1998) and to stabilize
a “twisted clamp” homodimer conformation discernible by
nuclear magnetic resonance (Lee et al., 1998; Shin et al.,
2001). This suggests that a ternary complex between synde-
can-4, PIP2, and PKC  may form in cells. Integrin ligation
has been shown to activate PI-5 kinase, the enzyme that cat-
alyzes the production of PIP2 (McNamee et al., 1993), sup-
porting the close functional link between syndecans and in-
tegrins. PIP2 has a wide variety of functions, including the
conversion of several cytoskeletal proteins (ERM proteins,
vinculin, and talin; Gilmore and Burridge, 1996; Hamada et
al., 2000; Martel et al., 2001) from inactive to active forms,
and it may be that PIP2 binding to syndecans is a necessary
step for the recruitment of these molecules to  5 1-contain-
ing focal adhesions. In addition, PKC  has been shown to
associate with the ERM protein ezrin (probably subsequent
to its release from membrane receptors such as CD44; Legg
et al., 2002), phosphorylates its COOH-terminal phosphor-
ylation on the T567 site, and thereby facilitates its confor-
mational activation (Ng et al., 2001; Bretscher et al., 2002;
Gautreau et al., 2002). Therefore,  5 1 integrin-derived
signals may stimulate ERM activities through both PIP2-
and PKC-dependent mechanisms. By contrast, the direct
binding of paxillin to  4 1 provides a direct link to vincu-
lin, and therefore talin.
It is also conceivable that the functions of PKC  are re-
quired during trafficking of integrin receptors, as studies
from our laboratories and others have previously demon-
strated close intracellular associations in recycling compart-
ments between integrin  1 and PKC  (Ng et al., 1999a;
Podar et al., 2002) and  1 and PKC  (Ivaska et al., 2002)
by biochemical and fluorescence resonance energy transfer
analysis. These findings may be reconciled with the data in
Figure 9. Isoform specificity of the effects of dominant-negative 
PKC  on  5 1-dependent migration. A375-SM cells were transiently 
transfected with various pEGFP-PKC constructs and then tested for 
their ability to migrate into wounds on a 50K substrate in the presence 
of soluble H/0. Still images were captured at the indicated times 
after wounding, and separate phase, EGFP, and merged images are 
shown (from left to right). (A) pEGFP-PKC -K376M–transfected cells 
in the presence of 5 ng/ml TPA; (B) pEGFP-PKC -K281M–transfected 
cells in the absence of TPA; (C) pEGFP-PKC -WT in the presence of 
5 ng/ml TPA. Bars, 50  m.T
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this report if either a stable integrin–PKC  interaction at
the plasma membrane requires coreceptor function, or if the
integrin–PKC  associations in the two compartments differ
in their requirement for a coreceptor.
Finally, PKC–integrin interactions are likely to have im-
portant implications in growth factor–mediated cell migra-
tion. For instance, a constitutive PKC – 1 integrin com-
plex has been found in multiple myeloma cells and may play
a significant role in the development of a VEGF-responsive
migratory phenotype (Podar et al., 2002). Furthermore, per-
turbation of PKC–integrin interaction blocks carcinoma cell
chemotaxis (Parsons et al., 2002). This may provide an im-
portant mechanism for explaining the well-documented
cross-talk between growth factor receptor- and integrin-me-
diated processes (Wang et al., 1998).
Materials and methods
Antibodies
The mouse mAbs 9E9, 16E6, 39B6, 36C9, 26G10, 10G6, 19B7, and 18D8,
which recognize the HepII/IIICS region of human FN, were raised in the
Humphries laboratory (Mostafavi-Pour et al., 2001). Mouse mAb 150.9,
raised against an NH2-terminal peptide from the human syndecan-4 core
protein (Longley et al., 1999), was a gift of Anne Woods (University of Ala-
bama, Birmingham, AL) and mouse monoclonal 5G9 was purchased from
Santa Cruz Biotechnology, Inc. Rat anti–human integrin  1 mAb13 was a
gift of Ken Yamada (National Institute of Dental and Craniofacial Research,
Bethesda, MD). Mouse anti–human integrin  4 mAb HP2/1 was purchased
from Serotec. Mouse mAb MC5, which recognizes the v3 region of PKC ,
and rabbit pAb PPA182, which recognizes phosphorylated T250 of PKC ,
have been reported previously (Ng et al., 1999b). Mouse anti–human vin-
culin (hVIN-1; 1:400 dilution) was purchased from Sigma-Aldrich.
Cloning and expression of recombinant FN fragments
cDNA clones encoding the H/120 and H/0 variants of the HepII/IIICS re-
gion of human FN (Fig. 1) were prepared as described previously
(Makarem et al., 1994) with some modifications (Mostafavi-Pour et al.,
2001). To create H/120-GAG-ABC, mutations (shown in bold) were intro-
duced into H/120 cDNA by site-directed mutagenesis (Kunkel, 1985) as
follows: GAG-A (residues 1697–1704 of FN using Swiss-Prot accession no.
PO2751; PPRRARVT to PPSSASVT), GAG-B (two oligonucleotides for resi-
dues 1936–1944, HGFRRTTPP to HGFSSTTPP, and residues 1950–1958,
IRHRPRPYP to ISHSPSPYP), and GAG-C (two oligonucleotides for resi-
dues 1817–1836, KYEKPGSPPREVVPRPRPRPGV to SYESPGSPPSEVVP-
SPSPGV, and residues 1858–1872, KNNQKSEPLIGRKKT to SNNQSSEP-
LIGSSST). The 50K CCBD of human FN was produced and purified as
described previously (Mould et al., 1997).
Cell attachment
A375-SM cells, a human metastatic melanoma cell line (provided by Josh
Fidler, M.D. Anderson Hospital and University of Texas, Houston, TX)
were cultured as described previously (Kozlowski et al., 1984). Cell cul-
ture reagents were purchased from GIBCO BRL. Cell attachment assays
were performed as described previously (Mould et al., 1994; Mostafavi-
Pour et al., 2001).
Focal adhesion formation
13-mm diam glass coverslips were derivatized for 30 min with 250  l 1
mM m-maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce Chemical
Co.), washed three times with 1 ml Dulbecco’s PBS lacking divalent cat-
ions (PBS
 ), and coated for 1 h at RT with 250  l of adhesive substrate in
PBS
 . The solution was aspirated, and 250  l 10 mg/ml heat-denatured
BSA (Humphries et al., 1986) was added to each well for 30 min at RT.
The BSA was then aspirated and the coverslips were washed three times
with PBS
 . In all experiments, A375-SM cells were treated with 25  g/ml
cycloheximide for 2 h to prevent de novo matrix synthesis and were then
detached as described previously (Mostafavi-Pour et al., 2001). 10  g/ml
BIM (diluted 1:200 from a DMSO stock; Calbiochem) was added to cells
2 h before detachment. Cells were resuspended to 5   10
4 ml in DME/25
mM Hepes, 0.5 ml aliquots were added to the coverslips, and the cells
were incubated for 2 h at 37 C. To test either the effect of soluble heparin-
binding fragment (H/0) or clustering of syndecan-4 by anti-syndecan-4 an-
tibody, cells were allowed to spread for 2 h on 50K before the addition of
H/0 or antibody for 30 min. Cells were fixed either directly for 20 min at
RT with 50  l 37% (wt/vol) formaldehyde, or unattached cells were re-
moved by two gentle washes with 1 ml PBS
 , and remaining cells fixed for
20 min at RT with 250  l 3% (wt/vol) formaldehyde diluted in PBS
 . Cov-
erslips were washed with PBS
  and then the formaldehyde was quenched
with 0.1 M glycine in PBS
  for 20 min at RT. Cells were permeabilized for
4 min at RT with 0.5% (wt/vol) Triton X-100 diluted in PBS
 , washed three
times with PBS
 , and then blocked for 1 h at RT or overnight at 4 C with
3% (wt/vol) BSA in PBS
  (blocking buffer). Primary antibodies were diluted
in blocking buffer and incubated for 1 h at RT. After washing, antibodies
were detected using TRITC-conjugated goat anti–rat IgG (1:100 dilution)
and/or FITC-conjugated donkey anti–mouse IgG (1:100 dilution; Jackson
ImmunoResearch Laboratories) in blocking buffer for 30 min. F-actin was
detected using rhodamine-conjugated phalloidin (1:1,000 dilution; Sigma-
Aldrich) in blocking buffer for 30 min. Coverslips were washed three times
with PBS
  and stained with 250  l 20 ng/ml DAPI (Sigma-Aldrich) in PBS
 
for 30 s. Coverslips were mounted face down onto microscope slides using
5  l Vectashield
® (Vector Laboratories), viewed on a microscope (Leica),
and immunofluorescence images were taken in the green (FITC) and red
(TRITC/rhodamine) channels using a CCD camera. Basic image acquisition
and analysis was performed using IPLab software v3.2. Advanced image
analysis was performed using Adobe Photoshop
® v5.0.
PKC activation
3   10
6 A375-SM cells were resuspended in 300  l 4  Laemmli SDS sam-
ple buffer, with 1 mM sodium vanadate, 1 mM PMSF, 10  g/ml aprotinin,
10  g/ml leupeptin, and 5  g/ml DNase, and were incubated on ice for 45
min. Cell debris was removed by centrifugation at 25,000 g for 30 min
at 4 C. Supernatants were analyzed by 4–12% SDS-PAGE using the
NuPAGE
® Novex Bis-Tris gel system (Invitrogen). Gels were transferred to
0.45  m nitrocellulose (Schleicher and Schuell) at 10 V (limit 0.5 A) for 30
min. Nonspecific binding sites on nitrocellulose membranes were blocked
for 1 h at RT with 3% (wt/vol) BSA in 150 mM NaCl, 10 mM Tris-HCl, pH
7.4, containing 0.1% (wt/vol) Tween-20 (TBS-Tween) as described previ-
ously (Ng et al., 1999b; Parekh et al., 2000). Membranes were then incu-
bated for 16 h at 4 C with either MC5 mouse anti–human PKC  diluted
1:500 in 3% (wt/vol) BSA in TBS-Tween for 1 h, or PPA182 rabbit anti-
activated human PKC  diluted 1:2,000 in 1% (wt/vol) skimmed milk pow-
der, 1% (wt/vol) BSA, and TBS-Tween. PPA182 was incubated in the pres-
ence of 1  g/ml cognate dephosphorylated peptide to block nonspecific
binding of the pAb to the nonphosphorylated form of PKC  (Ng et al.,
1999b; Parekh et al., 2000). After three washes with TBS-Tween for 10
min, HRP-conjugated goat anti–mouse (1:1,000 dilution in blocking
buffer; Dako) or anti–rabbit IgG (1:4,000 dilution) were added and incu-
bated for 1 h. After three 10-min washes with TBS-Tween, proteins were
detected using ECL substrate (NEN Life Science Products).
Wound migration assay
35-mm dishes with 14-mm glass bottoms (MatTek) were coated with either
H/120 (10  g/ml in PBS
 ) or 50K (50  g/ml in PBS
 ) for 1 h, and were
blocked with 10 mg/ml heat-denatured BSA (Humphries et al., 1986) for 30
min at RT. A375-SM cells were detached as described previously (Mos-
tafavi-Pour et al., 2001). 2   10
5 cells in complete medium (10% FCS-
MEM) were seeded for 16 h at 37 C in a humidified chamber with 5% CO2
until the cells formed a confluent monolayer. 5  g/ml H/0 was added to the
cells at the time of wounding when 50K was used as a substrate. Before
wounding, the cell layer was washed two times with PBS
 , the medium
was replaced, and then the cell monolayer was wounded along the center
of the dish using a sterile P10 pipette tip. To test the effect of either anti- 4
antibody (HP2/1), PKC inhibitor (BIM), or PKC activator (TPA) on migration,
HP2/1 was added to the medium at a concentration of 10  g/ml just before
wounding, or 10  g/ml BIM or 5 ng/ml TPA were added to the medium just
before videomicroscopy, i.e., 6 h after wounding. The wound width was
consistently between 270–300  m (285   15  m, n   30) 1 h after wound-
ing, when the wound had stabilized. Images were taken using a microscope
(Axiovert 135; Carl Zeiss MicroImaging, Inc.) equipped with a 20  0.3 NA
objective and a CCD camera (Photometrics Quantix; Roper Scientific). Ba-
sic image acquisition and analysis was performed using IPLab software
v3.2. The images were processed using Adobe Photoshop
® v5.0. Move-
ment was also studied by observing cells using time-lapse video micros-
copy. The images were taken using a 20  objective at 5-min intervals for 6 h
and organized into time-lapse movies using the IPLab image software.
Transfection
To assess the isoform specificity of PKC signaling during integrin-mediated
migration, A375-SM cells were transiently transfected with wild-type andT
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dominant-negative pEGFP-PKC constructs. These were as follows: wild-
type pEGFP-PKC , pEGFP-PKC  and pEGFP-PKC , pEGFP-PKC -A25E
(pseudosubstrate site mutation), pEGFP-PKC -A25E-K368M (pseudosub-
strate site and kinase-dead, ATP-binding mutations), pEGFP-PKC -T497A
(kinase-dead, substrate-binding mutant), pEGFP-PKC -K376M (kinase-
dead, ATP-binding mutant), and pEGFP-PKC -K281M (kinase-dead, ATP-
binding mutant). pEGFP-PKC  was constructed by subcloning the SacII/
StuI fragment from bovine PKC  into pEGFP-C2 (BD Biosciences; CLON-
TECH Laboratories, Inc.) digested with SacII/SmaI. The various pEGFP-
PKC  mutants were constructed using the same strategy using the
constructs as described previously (Bornancin and Parker, 1997). The
pEGFP-PKC  and pEGFP-PKC -K376M plasmids have been described pre-
viously (Srivastava et al., 2002). The pEGFP-PKC  plasmid was constructed
in two steps. A blunted 1.2-kb NdeI/PmeI fragment from pcDNA3.1-PKC 
was ligated into pEGFP-C1 (CLONTECH Laboratories, Inc.) cut with SmaI
to make pEGFP-PKM . PEGFP-PKC  was constructed by cutting pEGFP-
PKM  with BspE1/EcoRV and ligating in a fragment from pcDNA3.1-PKC 
cut with NgoMIV/EcoRV. The kinase-dead pEGFP-PKC -K281M plasmid
was constructed by cutting pEGFP-PKC  with NotI/XbaI and ligating in the
same fragment from pcDNA3-PKC -K281M (provided by Anne LeGood,
Cancer Research UK Laboratories). All constructs were confirmed by se-
quencing and expression by Western blot. Transfection of A375-SM cells
was conducted in 6-well culture plates (Costar). Cells were detached using
0.05% (wt/vol) trypsin, 0.02% (wt/vol) EDTA in PBS
  and seeded at 10
5
cells/ml in 2 ml growth medium. Cells were transfected the next day using
the LipofectAMINE™ 2000 protocol (Invitrogen), when the culture
reached 80–90% confluence. Transfected cells were detached (as de-
scribed under Wound migration assay) and seeded onto 35-mm dishes for
wounding assays after 48 h of transfection.
Online supplemental material
Video 1 shows A375-SM melanoma cells on 50K with soluble H/0 in the
presence of BIM. Video 2 shows A375-SM melanoma cells on 50K with
soluble H/0 in the presence of DMSO. Video 3 shows A375-SM melanoma
cells on H/120 in the presence of BIM. Video 4 shows A375-SM mela-
noma cells on H/120 in the presence of DMSO. Video 5 shows pEGF-
PKC -WT–transfected cells on 50K with soluble H/0 in the presence of 5
ng/ml TPA. Video 6 shows pEGF-PKC A25E-K368M–transfected cells on
50K with soluble H/0 in the absence of TPA. Video 7 shows pEGF-
PKC A25E-K368M–transfected cells on 50K with soluble H/0 in the pres-
ence of 5 ng/ml TPA. Video 8 shows pEGF-PKC A25E-K368M–transfected
cells on H/120 in the presence of 5 ng/ml TPA. Video 9 shows pEGF-
PKC -K376M–transfected cells on 50K with soluble H/0 in the presence of
5 ng/ml TPA. Video 10 shows pEGF-PKC -K281M–transfected cells on
50K with soluble H/0 in the absence of TPA. Video 11 shows pEGF-PKC -
WT–transfected cells on 50K with soluble H/0 in the presence of 5 ng/ml
TPA. Online supplemental material available at http://www.jcb.org/cgi/
content/full/jcb.200210176/DC1.
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